NSE filing, NSE: MANKIND. Summary written from the filing by ALFA Finder's alert engine.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,490.00
- Market cap
- ₹1,02,848 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 45.9×Sector 46.1×
- Promoter holding
- 72.62%-0.01% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
- Call
- Guides 20% growth
Mankind Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma Results Update
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma Acquisition
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Mankind Pharma Q2 FY27 Results: Net Profit ₹716.1 Cr, Up 37.7% YoY
Mankind Pharma Ltd reported revenue from operations of ₹4,338 Cr (+17.3% YoY) and net profit of ₹716.1 Cr (+37.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹716.1 Cr · +37.7% YoY
Mankind Pharma Other Announcement
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Other employee stock options announcements
All →Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.
Maxvolt Energy Industries Employee Stock Options
Maxvolt Energy granted 5,01,726 ESOPs to six employees under its MEIL ESOP 2025 scheme at exercise prices of ₹30 and ₹45. Options vest over four years, with exercise windows following vesting.
- Execution
- Vesting over 4 years from grant (25% at 2nd, 25% at 3rd, 50% at 4th anniversary); exercise over 3 years from each vesting date